featured-image

Cellular Origins, a TTP Company, focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), today announced the appointment of Geoffrey Hodge to its Board as Non-Executive Director (NED). Leveraging extensive expertise, knowledge and experience in cell therapy and biomanufacturing, Geoff’s appointment will strengthen the Company’s strategic vision and technical capability to deliver accelerated growth and continued commercial success. Geoff was most recently CEO of SOTIO Biotech US and CTO of Unum Therapeutics, both autologous cell therapy companies.

Prior to entering the cell therapy sector, Geoff co-founded Xcellerex, where he was the primary inventor of the XDR single-use bioreactor and head of the CDMO biomanufacturing services business, which helped the company grow to $50M in revenue prior to its acquisition by GE Healthcare. In addition to his role on the Board of Cellular Origins, Geoff will remain part of the Company’s Scientific Advisory Board, where his extensive experience in developing biomanufacturing technology and proven commercial success has already helped to shape the Company’s strategic direction. As NED, Geoff will work closely alongside the Board and leadership team to accelerate growth and ensure continued development of the Company’s robotic platform for cost- and space-efficient manufacture of cell therapies, ConstellationTM.



Cellular Origins recently acquired IP to the ACTIA (Autologous Cell T.

Back to Health Page